Last reviewed · How we verify
NCT06042309
Contact Allergy to Rubber Accelerators - a Clinical Study
NA trial testing Rubber accelerators and control chamber/solution for NON-SLS group in Contact Allergy in 18 participants. Completed in 20 December 2024.
20 December 2024
Quick facts
| Lead sponsor | National Allergy Research Center, Denmark |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 18 |
| Start date | 5 February 2024 |
| Primary completion | 20 December 2024 |
| Estimated completion | 20 December 2024 |
| Sites | 2 locations across Denmark |
Drugs / interventions tested
- Rubber accelerators and control chamber/solution for NON-SLS group
- SLS
- Rubber accelerators and control chamber/solution for SLS group
- Patch test on back
Conditions studied
- Contact Allergy — all drugs for Contact Allergy →
Sponsor
National Allergy Research Center, Denmark
Who can join
18 and older, any sex, with Contact Allergy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will investigate what concentrations of the most common thiurams and carbamates that elicit allergic contact dermatitis under patch test and what concentrations of the rubber accelerators that elicit allergic contact dermatitis by repeated exposures under simulated use conditions. Further, it will investigate whether a damaged skin barrier as caused by wet work increase the severity of the allergic contact dermatitis. The participants will be assigned to either the SLS (sodium lauryl sulfate)-group or non SLS-group. For the participants of the SLS-group, one volar forearm will be randomized to be pre-irritated with a soap i.e. detergent: sodium lauryl sulfate (SLS) for 24 hours to simulate wet work. The participants of the non SLS-group will not be pre-irritated with SLS. Following this, the participants' volar forearms will be exposed to thiurams or carbamates and a control solution every night for 7 nights to simulate the repeated exposure to rubber gloves with accelerators. The skin reactions will be read cf. current international guidelines and further quantified using laser Doppler flowmetry. During the study, all participants will be patch tested on the upper back with rubber accelerators to investigate their current degree of sensitization and the dose-response relationships.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Thresholds for Contact Allergy to a Rubber Accelerator: TETD-Determined by Serial Dilution Patch Testing and a Simulated Glove-Use Model.
Kursawe Larsen C, Johansen JD, Zachariae C, Svedman C, et al · · 2025 · cited 3× · PMID 40375756 · DOI 10.1111/cod.14817
Verify or expand the search:
- PubMed search for NCT06042309
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other National Allergy Research Center, Denmark trials
Trials by the same sponsor.
- NCT06130462 — Detection of Aluminium-reactive T-lymphocytes in Patients With Vaccination Granulomas · NA · completed
- NCT04921163 — Children With Aluminium Contact Allergy: Oral Exposure Study · NA · completed
- NCT04438330 — The Immunological Profile of Nickel Dermatitis · NA · completed
- NCT04790799 — Occupational Hand Eczema - Testing of a Prevention-concept · NA · completed
- NCT04438135 — Children With Aluminium Contact Allergy: Cutaneous Exposure Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06042309 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Allergy Research Center, Denmark
- Last refreshed: 17 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06042309.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing